Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Sunitinib Stories

2006-06-04 06:06:43

By Toni Clarke ATLANTA (Reuters) - Wyeth said on Sunday that interim results of a late-stage trial of its experimental kidney cancer drug significantly increased survival in patients compared to standard therapy. Patients with advanced kidney cancer who took the drug, temsirolimus, had a median survival time of 10.9 months, compared to a survival time of 7.3 months for patients who took the standard therapy. Data from the late-stage, or Phase III, trial were presented at the annual...

2006-06-04 06:01:57

By Ransdell Pierson NEW YORK (Reuters) - Pfizer Inc.'s kidney cancer drug Sutent will soon become the favored first-line treatment for advanced forms of the disease, based on its ability to prolong survival in a late-stage trial described on Sunday, researchers said. Sutent was approved in January as a second-line treatment for advanced kidney cancer, meaning for patients whose cancer spread despite their earlier use of the standard drugs interferon and interleukin-2, which are...

2006-06-03 15:11:46

By Toni Clarke ATLANTA (Reuters) - Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say. Early studies show that combining targeted treatments such as Genentech Inc.'s breast cancer drug Herceptin with GlaxoSmithKline Plc's experimental treatment Tykerb, may be helpful in patients who do not respond to Herceptin alone, said Dr. Jose...

2006-06-03 13:00:00

By Ransdell Pierson NEW YORK -- A Pfizer Inc. kidney cancer drug has also shown promise in a small mid-stage trial as a treatment for the most common form of lung cancer, researchers said on Saturday. The new study involved 63 patients whose non-small cell lung cancer had progressed despite earlier treatments with standard chemotherapy. All patients were then given Pfizer's once-daily pill, Sutent, as a stand-alone treatment and continued to take it until their disease progressed. Tumors...

2005-12-21 09:44:55

By Susan Heavey WASHINGTON (Reuters) - The U.S. Food and Drug Administration approved a new drug to treat the most common type of kidney cancer on Tuesday, hailing it as a major advance in slowing tumor growth. The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., helped curb the size and number of tumors, although it has not yet been shown to help patients live longer, the FDA said. It is the first drug approved to treat advanced kidney cancer since...

2005-12-20 18:46:48

By Susan Heavey WASHINGTON (Reuters) - The U.S. Food and Drug Administration approved a new drug to treat the most common type of kidney cancer on Tuesday, hailing it as a major advance in slowing tumor growth. The drug Nexavar, made by German drugmaker Bayer AG and Onyx Pharmaceuticals Inc., helped curb the size and number of tumors, although it has not yet been shown to help patients live longer, the FDA said. It is the first drug approved to treat advanced kidney cancer since...

2005-11-03 14:47:04

Paris, France, Thursday 3 November 2005 - Updated results from a Phase III trial presented at the 13th European Cancer Conference (ECCO) show that sunitinib (SU11248) prolongs both progression-free and overall survival in patients with progressive metastatic and/or unresectable GIST whose disease has failed to respond to the standard therapy - imatinib mesylate. This study was a double-blind, placebo-controlled, international, multicentre, Phase III trial involving 312 patients with GIST...

2005-09-08 08:06:36

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON, Sept 8 - Pfizer Inc is ready to launch a patient-monitoring scheme to assess the safety of its novel inhaled-insulin drug Exubera if the product is approved for use, its worldwide head of development said on Thursday. Exubera is being developed with Sanofi-Aventis SA and Nektar Therapeutics, and is due to be reviewed by a U.S. Food and Drug Administration (FDA) panel later on Thursday. Most industry analysts expect a...

2004-11-30 15:00:10

GROTON, Conn., Nov. 30 /PRNewswire-FirstCall/ -- Pfizer Inc said today it is on track to achieve its goal of submitting 20 New Drug Application (NDA) filings in the five-year period ending in 2006, reflecting the industry's premier research and development pipeline. In a presentation to financial analysts at the company's largest research and development site, Pfizer said it will have completed 12 of these 20 regulatory filings by the end of 2004. Pfizer also announced that its drug...